Key Takeaways for Early Relapse Multiple Myeloma Management

In this concluding segment on early relapse multiple myeloma, Luciano Costa invites Carol Ann Huff to summarize key clinical insights from the discussion. Dr. Huff highlights that emerging phase 3 data have significantly reshaped the treatment landscape, with BCMA-directed bispecific antibodies demonstrating high response rates, durable outcomes, and manageable safety profiles in patients with one to three prior lines of therapy. She emphasizes that clinicians now have more effective and well-tolerated options earlier in the disease course, requiring thoughtful integration into practice. Key considerations include patient fitness, prior treatment exposure, and individualized risk assessment, alongside proactive management of infections and other toxicities. The discussion underscores that bispecific antibodies are increasingly becoming part of standard treatment strategies rather than reserved for later lines. Overall, this segment reinforces that treatment selection in multiple myeloma should be guided by a combination of clinical evidence, patient-specific factors, and shared decision-making.